

IN THE CLAIMS:

Please amend claim 34 to read as follows:

34. (Twice amended) The method of any of claims 24-26, wherein a marker gene is inserted into one or more of said inactivated genes.

Please add new claims 88 and 89 as follows:

88. (New) The method of any of claims 50-52, wherein a marker gene is inserted into each inactivated gene.

89. (New) The *Shigella* of claim 54 or 55, wherein a marker gene is inserted into each inactivated gene.

REMARKS

With entry of this amendment, claims 24-30, 32-37, 39-41, 43-57, 74-81, and 88-89 are pending in this application.

Applicants submit that the amendment of claim 34 does not change the scope of the claim or add new matter, as claim 34 originally depended from claims 24-26, albeit via claim 33.

New claims 88 and 89 add a limitation to claims 50-52 and 54-55. This limitation is already claimed in claims 43 and 44, in relation to a different embodiment.

For the above reasons, applicants respectfully submit that the new claims do not present new issues or require an additional search.

Applicants courteously request the timely entry of this Amendment. Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com